Case 24-80040-sgj11 Doc 862 Filed 05/02/25 Fntered 05/02/25 06:42:40 Desc. Main Document Falls 1 to 10. Main Document Main Document Page 1 01 10 UNITED STATES BANKRUPTCY COURT

_	Northern DISTRICT OF	<u>Texas</u>
In re: EB Pharma LLC		Case No. 24-80042 Lead Case No. 24-80040
Debtor(s)		
Post-confirmation Repo	ort	Chapter 11
Quarter Ending Date: 03/31/2025		Petition Date: <u>04/01/2024</u>
Plan Confirmed Date: 09/05/2024		Plan Effective Date: 09/30/2024
This Post-confirmation Report relates	to: • Reorganized Debtor • Other Authorized Party or Entit	ty:
	,,,	Name of Authorized Party or Entity
/s/ Gary Broadbent Signature of Responsible Party		Broadbent ed Name of Responsible Party
05/02/2025		
Date	<u>1209</u> Addre	Orange Street, Wilmington, Delaware 19801

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Case 24-80040-sgj11 Doc 862 Filed 05/02/25 Entered 05/02/25 06:42:40 Desc Main Document Page 2 of 10

Debtor's Name EB Pharma LLC Case No. 24-80042

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$0	\$0
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$0	\$0

: Freco	nfirmation Professional	rees and Expenses	A 1	A 1	Doid C	Paid
			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulativ
Profes	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor Aggregate Total					
Itemiz	ed Breakdown by Firm					
	Firm Name	Role				
i						
ii						
iii						
iv						
v						
vi						
vii						
viii						
ix						
X						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxvii						
xxix						

Case 24-80040-sgj11 Doc 862 Filed 05/02/25 Entered 05/02/25 06:42:40 Desc Main Document Page 3 of 10

Debtor's Name EB Pharma LLC

Case No. 24-80042

xxx					
xxxi					
xxxii					
xxxiii					
xxxiv					
xxxv					
xxxvi					
xxxvii					
xxxvii					
xxxix					
xl					
xli					
xlii					
xliii					
xliv					
xlv					
xlvi					
xlvii					
xlviii					
xlix					
1					
li					
lii					
liii					
liv					
lv					
lvi					
lvii					
lviii					
lix					
lx					
lxi					
lxii					
lxiii					
lxiv					
lxv					
lxvi					
lxvii					
lxviii					
lxix					
lxx					
lxxi					
	İ	I.	I	I.	1

Case 24-80040-sgj11 Doc 862 Filed 05/02/25 Entered 05/02/25 06:42:40 Desc Main Document Page 4 of 10

Debtor's Name EB Pharma LLC Case No. 24-80042

lxxii			
lxxiii			
lxxiv			
lxxv			
lxxvi			
lxxvii			
lxxviii			
lxxix			
lxxx			
lxxxi			
lxxxii			
lxxxiii			
lxxxiv			
lxxxv			
lxxxvi			
lxxxvi			
lxxxvi			
lxxxix			
xc			
xci			
xcii			
xciii			
xciv			
xcv			
xcvi			
xcvii			
xcviii			
xcix			
c			
ci			

					Approved	Approved	Paid Current	Paid
					Current Quarter	Cumulative	Quarter	Cumulative
b.		sional fees & expenses (nonled by or on behalf of the deb		ate Total				
	Itemize	ed Breakdown by Firm						
		Firm Name	Role					
	i							
	ii							
	iii							
	iv							
	v							
	vi							

Case 24-80040-sgj11 Doc 862 Filed 05/02/25 Entered 05/02/25 06:42:40 Desc Main Document Page 5 of 10

Case No. 24-80042

Debtor's Name EB Pharma LLC

	vii			
	viii			
	ix			
	х			
	xi			
	xii			
	xiii			
	xiv			
	xv			
	xvi			
	xvii			
	xviii			
	xix			
	xx			
	xxi			
	xxii			
	xxiii			
	xxiv			
	xxv			
	xxvi			
	xxvii			
	xxviii			
	xxix			
	xxx			
	xxxi			
	xxxii			
	xxxiii			
	xxxiv			
	xxxv			
	xxxvi		 	
	xxxvii			
	xxxvii		 	
	xxxix		 	
	xl			
	xli			
	xlii			
	xliii			
	xliv			
ļ	xlv			
	xlvi			
	xlvii			
	xlviii			

Case 24-80040-sgj11 Doc 862 Filed 05/02/25 Entered 05/02/25 06:42:40 Desc Main Document Page 6 of 10

Debtor's Name EB Pharma LLC Case No. 24-80042

X X X X X X X X X X
Iiii
Iiv
Ivi
Vii
Ivii
Iviii
lix
Ixi
Ixii
Ixiii
Ixiv
Ixvi
Ixvii
Ixvii
Ixviii
Ixx
lxxi
Ixxii
lxxii
Ixxiii
lxxv lxxvi lxxvii
lxxvi lxxvii
lxxvii
lxxvii
lxxviii
lxxix
lxxx
lxxxi
lxxxii
lxxxiii
lxxxiv
lxxxv
lxxxvi
lxxxvi
lxxxvi
lxxxix

Case 24-80040-sgj11 Doc 862 Filed 05/02/25 Entered 05/02/25 06:42:40 Desc Main Document Page 7 of 10

All professional fees and expenses (debtor & committees)

c ci

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$0	\$0	0%
b. Secured claims	\$0	\$0	\$0	\$0	0%
c. Priority claims	\$0	\$0	\$0	\$0	0%
d. General unsecured claims	\$0	\$0	\$0	\$0	0%
e. Equity interests	\$0	\$0	\$0		

\$0

\$0

\$0

\$0

Part 4: Questionnaire	
a. Is this a final report?	Yes O No •
If yes, give date Final Decree was entered:	
If no, give date when the application for Final Decree is anticipated:	
b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?	Yes No

Case 24-80040-sgj11 Doc 862 Filed 05/02/25 Entered 05/02/25 06:42:40 Desc Main Document Page 8 of 10

Debtor's Name EB Pharma LLC Case No. 24-80042


Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).


I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ Gary Broadbent	Gary Broadbent
Signature of Responsible Party	Printed Name of Responsible Party
Plan Administrator	05/02/2025
Title	Date


Debtor's Name EB Pharma LLC Case No. 24-80042




Page 1




Other Page 1




Page 2 Minus Tables




Bankruptcy Table 1-50




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3. Part 4. Last Page